Global Atherosclerosis Treatment Drugs Market Is Estimated To Witness High Growth Due To Increasing Incidences Of Atherosclerosis And Growing Geriatric Population
Overview:
Cardiovascular disease is the leading cause of death in western countries and atherosclerosis is the underlying pathology of most major adverse cardiovascular events (MACE), which include heart attack and stroke. Despite therapeutic efforts to lower blood cholesterol levels and to address other risk factors, MACE remain a persistent problem. The most promising agents in atherosclerosis treatment are those that target inflammation, which is the main inflammatory mediator in atherosclerotic diseases.
These agents include anti-inflammatory cytokines and IL-1R inhibitors. Vascular catheterization is often performed to pinpoint specific arteries that have narrowed or become blocked by atherosclerotic plaques. This is done by inserting a long, thin tube called a catheter through a vein into the artery and taking x-rays to locate plaque deposits. If the arteries are severely narrowed, a procedure called angioplasty and stent placement is performed to open the artery.
Market Dynamics:
Growing acquisitions are estimated to augment growth of the global Atherosclerosis Treatment Drugs Market over the forecast period. For instance, Prevail Therapeutics Inc., was acquired by Pfizer Inc., in October 2020. Prevail Therapeutics is a gene therapy company that is aiming to strengthen their portfolio in rare neurological diseases. Moreover, increasing strict regulatory approvals are anticipated to restrain growth of the global atherosclerosis treatment drugs for market over the forecast period.
Due to the rising prevalence of zoonotic illnesses and the growing number of chickens worldwide, the Poultry Vaccines Market is expanding rapidly.
Impact of COVID-19:
The pandemic led to shutting down of manufacturing units and disrupted many supply chains. This affected the production activities. The pandemic also had a severe impact on the healthcare sector of many countries. Hospitals were running on full capacity and they were facing shortage of drugs, medical equipment and skilled professionals.
The pandemic had a significant impact on the other diseases as doctors were prioritizing COVID-19 patients. This led to delay in treatment of other disease like cardiovascular diseases, cancer and atherosclerosis. This had a negative impact on the growth of the global Atherosclerosis Treatment Drugs Market. However, the market is expected to witness growth as several restrictions have been relaxed.
Key Takeaways:
The global Atherosclerosis Treatment Drugs Market is expected to witness high growth, exhibiting CAGR of 2.5 % over the forecast period, due to increasing product approvals.
For instance, Novartis received approval from the US FDA for their first and only small interfering RNA (siRNA) therapy in December 2021.
North America is anticipated to witness significant growth in the global atherosclerosis treatment drugs for market over the forecast period, owing to growing healthcare infrastructure and increasing prevalence of cardiovascular diseases.
Major players operating in the global Atherosclerosis Treatment Drugs Market are Eli Lilly and Company, Pfizer Inc., Mylan N.V., AstraZeneca, Bayer AG, Merck & Co., Inc., GlaxoSmithKline Plc, Regeneron Pharmaceuticals, Inc., Novartis AG, and Amgen Inc.

Comments
Post a Comment